ECM
SRNE

ExodusPoint Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

ExodusPoint Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-30,000
Closed -$143K – 1400
2019
Q1 		$143K Buy
+30,000
New +$78.7K 0.01% 596

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRF
B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

ExodusPoint Capital Management's SRNE Position: Q4 2022 in Review

ExodusPoint Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 44,233 shares — an estimated $69K sold.

ExodusPoint Capital Management first reported a position in SRNE in Q3 2020 and held it in 5 quarters. The position peaked at $740K in Q2 2021. 223 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

  • ExodusPoint Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 44,233 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $69K.
  • ExodusPoint Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 5 quarters.
  • ExodusPoint Capital Management's Sorrento Therapeutics, Inc. position peaked at $740K in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on ExodusPoint Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.